MPM: NextPoint Therapeutics Closes $42.5 Million To Develop New Class Of Precision Oncology Therapeutics

NextPoint Therapeutics - a clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway - announced the closing of a $42.5 million Extension to its Series B financing round resulting in a total of $122.5 million raised in the Series B financing. The post NextPoint Therapeutics Closes $42.5 Million To Develop New Class Of Precision Oncology Therapeutics appeared first on Pulse 2.0.